{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:43:21Z","timestamp":1777340601777,"version":"3.51.4"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.maturitas.2008.03.009","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T04:17:54Z","timestamp":1210652274000},"page":"78-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical experiences with drospirenone: From reproductive to postmenopausal years"],"prefix":"10.1016","volume":"60","author":[{"given":"Faustino R.","family":"P\u00e9rez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2008.03.009_bib1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2008.03.009_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2008.03.009_bib3","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2008.03.009_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2008.03.009_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2008.03.009_bib6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2008.03.009_bib7","first-page":"2028","volume":"28","author":"Collins","year":"2007","journal-title":"Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J"},{"key":"10.1016\/j.maturitas.2008.03.009_bib8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2008.03.009_bib9","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/humrep\/dem031","article-title":"Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy","volume":"22","author":"Tannen","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.maturitas.2008.03.009_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-73-4-837","article-title":"Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women","volume":"73","author":"Oelkers","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.03.009_bib11","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.03.009_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0010-7824(92)90121-9","article-title":"Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins","volume":"46","author":"Pollow","year":"1992","journal-title":"Contraception"},{"issue":"i\u2013vii","key":"10.1016\/j.maturitas.2008.03.009_bib13","first-page":"1","article-title":"Cardiovascular disease and steroid hormone contraception","volume":"877","author":"Report of a WHO Scientific Group","year":"1998","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.maturitas.2008.03.009_bib14_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential","volume":"54","author":"Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib14_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.AOG.0000107298.29343.6a","article-title":"Combination estrogen\u2013progestin contraceptives and body weight: Systematic review of randomized controlled trials","volume":"103","author":"Gallo","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.maturitas.2005.03.002","article-title":"Risk factors for high blood pressure in women attending menopause clinics in Italy","volume":"53","author":"Gruppo di Studio Progetto Menopausa Italia","year":"2006","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2008.03.009_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09513590601152177","article-title":"Effects of postmenopausal hormone replacement therapy on body fat composition","volume":"23","author":"Y\u00fcksel","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0010-7824(94)00015-O","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models","volume":"51","author":"Muhn","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/13625180008500407","article-title":"A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers","volume":"5","author":"Blode","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"Suppl. 3","key":"10.1016\/j.maturitas.2008.03.009_bib19","first-page":"19","article-title":"Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone","volume":"7","author":"Oelkers","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"Suppl. 3","key":"10.1016\/j.maturitas.2008.03.009_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13697130500330341","article-title":"Drospirenone in combination with estrogens: for contraception and hormone replacement therapy","volume":"8","author":"Oelkers","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2008.03.009_bib21","first-page":"255","article-title":"Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function","volume":"217","author":"Sch\u00fcrmann","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00003495-200767050-00001","article-title":"Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?","volume":"67","author":"Motivala","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.maturitas.2008.03.009_bib23","first-page":"2565","article-title":"Evaluation and treatment of women with hirsutism","volume":"67","author":"Hunter","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.maturitas.2008.03.009_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.contraception.2006.08.011","article-title":"Serum potassium monitoring for users of ethinyl estradiol\/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes","volume":"75","author":"Eng","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0091270006289973","article-title":"Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function","volume":"46","author":"Sch\u00fcrmann","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/09513590009167683","article-title":"Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers","volume":"14","author":"Oelkers","year":"2000","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.maturitas.2006.07.009","article-title":"Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism","volume":"55","author":"Palacios","year":"2006","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2008.03.009_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.gme.0000230348.05745.7d","article-title":"Drospirenone increases central and peripheral beta-endorphin in ovariectomized female rats","volume":"14","author":"Genazzani","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2008.03.009_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2265.1975.tb01557.x","article-title":"Gonadotrophin hormone releasing tests in women receiving hormonal contraception","volume":"4","author":"P\u00e9rez-L\u00f3pez","year":"1975","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.maturitas.2008.03.009_bib31","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0002-9378(99)70120-1","article-title":"The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices","volume":"181","author":"Rivera","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/13625180008500376","article-title":"Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol","volume":"5","author":"Rosenbaum","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.maturitas.2008.03.009_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13625180008500375","article-title":"Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone","volume":"5","author":"Huber","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.maturitas.2008.03.009_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","article-title":"An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen","volume":"61","author":"Parsey","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0015-0282(01)01834-9","article-title":"Effect of a combined oral contraceptive containing 3mg of drospirenone and 30\u03bcg of ethinyl estradiol on the human endometrium","volume":"76","author":"L\u00fcdicke","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2008.03.009_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20\u03bcg ethinylestradiol and 3mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13625180008500387","article-title":"A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel","volume":"5","author":"Foidart","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.maturitas.2008.03.009_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0010-7824(02)00537-1","article-title":"A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism","volume":"67","author":"Gaspard","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.contraception.2003.11.003","article-title":"A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles","volume":"69","author":"Gaspard","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.contraception.2005.02.002","article-title":"Prospective study on sexual behavior of women using 30\u03bcg ethinylestradiol and 3mg drospirenone oral contraceptive","volume":"72","author":"Caruso","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00024677-200605040-00006","article-title":"User experience with an oral contraceptive containing ethinylestradiol 30\u03bcg and drospirenone 3mg (yasmin((r))) in clinical practice","volume":"5","author":"Schultz-Zehden","year":"2006","journal-title":"Treat Endocrinol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.contraception.2004.04.004","article-title":"Short-term variations in bone remodeling markers of an oral contraception formulation containing 3mg of drospirenone plus 30\u03bcg of ethinyl estradiol: observational study in young postadolescent women","volume":"70","author":"Paoletti","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.AOG.0000148344.26475.fc","article-title":"Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density","volume":"105","author":"Nappi","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/ejc.6.3.167.171","article-title":"Transfer of drospirenone to breast milk after a single oral administration of 3mg drospirenone+30\u03bcg ethinylestradiol to healthy lactating women","volume":"6","author":"Blode","year":"2001","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.maturitas.2008.03.009_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00044011-200626030-00004","article-title":"Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20\u03bcg and drospirenone 3mg","volume":"26","author":"Cibula","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.maturitas.2008.03.009_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0010-7824(96)00137-0","article-title":"Shorter pill-free interval in combined oral contraceptives decreases follicular development","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib47","first-page":"261","article-title":"Hormone withdrawal symptoms in oral contraceptive users","volume":"95","author":"Sulak","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.contraception.2006.02.006","article-title":"Greater inhibition of the pituitary\u2013ovarian axis in oral contraceptive regimens with a shortened hormone-free interval","volume":"74","author":"Willis","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00006842-199001000-00007","article-title":"Relationship between premenstrual symptoms and oral contraceptive use: a controlled study","volume":"52","author":"Walker","year":"1990","journal-title":"Psychosom Med"},{"key":"10.1016\/j.maturitas.2008.03.009_bib50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200317050-00003","article-title":"The role of hormones and hormonal treatments in premenstrual syndrome","volume":"17","author":"Backstrom","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.maturitas.2008.03.009_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.contraception.2006.10.011","article-title":"The oral contraceptive containing 30\u03bcg of ethinylestradiol plus 3mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study","volume":"75","author":"Fruzzetti","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib52","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/humrep\/del162","article-title":"Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30\u03bcg ethinyl estradiol and 3mg drospirenone","volume":"21","author":"Milsom","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.maturitas.2008.03.009_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/ejc.8.1.37.51","article-title":"Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms","volume":"8","author":"Apter","year":"2003","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.maturitas.2008.03.009_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.contraception.2004.07.010","article-title":"A comparative study of monophasic oral contraceptives containing either drospirenone 3mg or levonorgestrel 150\u03bcg on premenstrual symptoms","volume":"71","author":"Sangthawan","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/15246090152543148","article-title":"PMS\/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder","volume":"10","author":"Freeman","year":"2001","journal-title":"J Womens Health Gend Based Med"},{"key":"10.1016\/j.maturitas.2008.03.009_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.fertnstert.2003.08.030","article-title":"Psychological effect of the oral contraceptive formulation containing 3mg of drospirenone plus 30\u03bcg of ethinyl estradiol","volume":"81","author":"Paoletti","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2008.03.009_bib57","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.contraception.2005.10.016","article-title":"Effect of a combination of ethinylestradiol 30\u03bcg and drospirenone 3mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception","volume":"74","author":"Borges","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib58","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00404-006-0280-6","article-title":"Efficacy of Yasmin in premenstrual symptoms","volume":"275","author":"Taneepanichskul","year":"2007","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.maturitas.2008.03.009_bib59","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib60","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","article-title":"Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation","volume":"72","author":"Pearlstein","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib61","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2006.05.012","article-title":"Oral contraceptives and premenstrual symptoms: comparison of a 21\/7 and extended regimen","volume":"195","author":"Coffee","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1526-4610.2007.00650.x","article-title":"Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval","volume":"47","author":"Sulak","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.maturitas.2008.03.009_bib63","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.contraception.2007.01.014","article-title":"Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen","volume":"75","author":"Coffee","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib64","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2003-031158","article-title":"Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study","volume":"89","author":"Guido","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.03.009_bib65","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.fertnstert.2005.07.1311","article-title":"Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism","volume":"85","author":"Batukan","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2008.03.009_bib66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/09637480601137066","article-title":"Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism","volume":"23","author":"Batukan","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13625180600983082","article-title":"Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome","volume":"12","author":"Pehlivanov","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.maturitas.2008.03.009_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.fertnstert.2006.11.137","article-title":"Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome","volume":"88","author":"De Leo","year":"2007","journal-title":"Fertil Steril"},{"issue":"4 Suppl.","key":"10.1016\/j.maturitas.2008.03.009_bib69","first-page":"2","article-title":"The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"van Vloten","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.maturitas.2008.03.009_bib70","first-page":"123","article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","volume":"74","author":"Thorneycroft","year":"2004","journal-title":"Cutis"},{"issue":"10 Suppl. 2","key":"10.1016\/j.maturitas.2008.03.009_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1524-6175.2004.03830.x","article-title":"Update on the management of hypertension: recent clinical trials and the JNC 7","volume":"6","author":"Moser","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.maturitas.2008.03.009_bib72","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17\u03b2-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension","volume":"112","author":"White","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2008.03.009_bib73","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000232179.60442.84","article-title":"Effects of a new hormone therapy, drospirenone and 17-\u03b2-estradiol, in postmenopausal women with hypertension","volume":"48","author":"White","year":"2006","journal-title":"Hypertension"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2008.03.009_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13697130601114933","article-title":"Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension","volume":"10","author":"White","year":"2007","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2008.03.009_bib75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjhyper.2004.12.003","article-title":"Effects of drospirenone\/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women","volume":"18","author":"Preston","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.maturitas.2008.03.009_bib76","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2796.2005.01571.x","article-title":"Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women","volume":"258","author":"Tank\u00f3","year":"2005","journal-title":"J Intern Med"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2008.03.009_bib77","first-page":"33","article-title":"Effects of drospirenone\/estrogen combinations on bone metabolism","volume":"18","author":"Christiansen","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib78","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.fertnstert.2006.11.206","article-title":"A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women","volume":"88","author":"Margolis","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2008.03.009_bib79","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.AOG.0000260956.61835.6d","article-title":"Oral contraceptive tolerance \u2013 does the type of pill matter?","volume":"109","author":"Moreau","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib80","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2165\/00002018-200427130-00003","article-title":"Safety of a new oral contraceptive containing drospirenone","volume":"27","author":"Heinemann","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.maturitas.2008.03.009_bib81","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib82","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.AOG.0000279448.62221.a8","article-title":"Risk of thromboembolism in women taking ethinylestradiol\/drospirenone and other oral contraceptives","volume":"110","author":"Seeger","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib83","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.contraception.2005.09.015","article-title":"A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20\u03bcg ethinyl estradiol and a reference containing desogestrel and 30\u03bcg ethinyl estradiol","volume":"73","author":"Kluft","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.maturitas.2008.03.009_bib84","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.fertnstert.2006.01.009","article-title":"WISE Study Group Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation","volume":"85","author":"Merz","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2008.03.009_bib85","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0021-9150(95)05599-R","article-title":"Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women","volume":"118","author":"Dallongeville","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.maturitas.2008.03.009_bib86","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.HYP.0000242482.57186.e8","article-title":"Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats","volume":"48","author":"Arias-Loza","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.maturitas.2008.03.009_bib87","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/humrep\/dem109","article-title":"Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors","volume":"22","author":"Simoncini","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.maturitas.2008.03.009_bib88","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1097\/00006250-200604001-00054","article-title":"Drospirenone and 17-\u03b2 estradiol reduces 24-h blood pressure in postmenopausal women with hypertension","volume":"107","author":"White","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib89","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.amjcard.2007.01.042","article-title":"Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris","volume":"99","author":"Knuuti","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.maturitas.2008.03.009_bib90","first-page":"29","article-title":"Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study","volume":"10","author":"Gelfand","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2008.03.009_bib91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.gme.0000227860.58097.e9","article-title":"Menopause and determinants of quality of life in women at midlife and beyond: the study of health in Pomerania (SHIP)","volume":"14","author":"Schwarz","year":"2007","journal-title":"Menopause"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512208001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512208001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:44:58Z","timestamp":1759913098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512208001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0378512208001084"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2008.03.009","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experiences with drospirenone: From reproductive to postmenopausal years","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2008.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}